Osteal Therapeutics

About Osteal Therapeutics

Osteal Therapeutics, Inc., founded in 2013 by Jude Paganelli and Dr. Brian de Beaubien, is a clinical-stage biopharmaceutical company focused on developing treatments for musculoskeletal infections. The company's leadership includes President and CEO David Thompson, who brings over two decades of experience in medical technology and healthcare commercialization. Co-founder Jude Paganelli, a seasoned medical technology entrepreneur with a background in mechanical engineering from M.I.T. and bioengineering from UC Berkeley, serves as Chief Technology Officer. Their collective expertise guides the company's mission to address the significant unmet needs in orthopedic infection treatment.

The company targets the market for periprosthetic joint infections (PJI), a severe complication of joint replacement surgery affecting over 40,000 people annually in the U.S. These infections involve bacterial biofilms on joint prostheses, which are difficult to treat with current methods. The current standard of care, two-stage exchange arthroplasty, can take an average of 16 weeks and has shown success rates below 50% after one year, often leading to disability and mortality.

Osteal's lead product is VT-X7, a drug-device combination therapy for treating PJI in hip and knee replacements. This system is designed to provide a rapid, seven-day treatment. The procedure involves the surgical removal of the infected prosthesis, followed by the placement of a proprietary VT-X7 spacer and fluid management system. Over a seven-day period, a high-concentration, localized formulation of vancomycin and tobramycin is continuously irrigated into the joint space to eradicate the infection. Afterwards, the spacer is removed and a new permanent prosthesis is implanted. Clinical trial data has shown that over 90% of patients treated with VT-X7 remained infection-free after one year, with a median time to revision of just seven days compared to 98 days for the standard of care.

Osteal operates on a business model centered on gaining FDA approval and commercializing its therapies. The company employs a low-risk development strategy by using already-approved drugs with established safety profiles, focusing on new local delivery methods. The company has successfully raised significant capital to fund its clinical trials and prepare for market launch, including a $50 million Series D financing round in June 2024 led by Zimmer Biomet. VT-X7 has received multiple FDA designations, including Breakthrough Therapy, Orphan Drug, Fast Track, and Qualified Infectious Disease Product, which help expedite its development and review process.